Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

NCT00042952 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

32

Enrollment

NIH

Sponsor class

Stopped Administratively complete.

Conditions

Ovarian Dysgerminoma
Recurrent Malignant Testicular Germ Cell Tumor
Recurrent Ovarian Germ Cell Tumor
Stage II Malignant Testicular Germ Cell Tumor
Stage II Ovarian Germ Cell Tumor
Stage III Malignant Testicular Germ Cell Tumor
Stage III Ovarian Germ Cell Tumor
Testicular Seminoma

Interventions

DRUG: imatinib mesylate
PROCEDURE: therapeutic conventional surgery
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)